Hospital.Help

Boston – The US Food and Drug Administration (FDA) has approved the active ingredient vorasidenib for patients with grade 2 gliomas with an IDH1 or IDH2 mutation. The basis for the approval is the “INDIGO” study (“Investigating Vorasidenib in Glioma”), a global, double-blind, randomized phase 3 clinical trial. Its results were published last summer in the New England Journal of Medicine (2023, DOI:…